Health Condition 1: L98- Other disorders of skin and subcutaneous tissue, not elsewhere classified Health Condition 2: null- patient admitted with sclerodactyly,difficulty in opening mouth ,dysphagia
Conditions
Interventions
Intervention1: drug - cyclophosphamide: All patients diagnosed of systemic sclerosis will be admitted as in patients and after obtaining informed consent, given intravenous cyclophosphamide 500mg in 5
Sponsors
Government medical college
Eligibility
Inclusion criteria
Inclusion criteria: All patients of systemic sclerosis, satisfying the ACR criteria for systemic sclerosis attending the Out Patient, Department of Dermatology in Calicut Medical College.
Exclusion criteria
Exclusion criteria: 1.Patients who have not given the consent to be a part of the study 2.Pregnant females 3.Patients with major organ involvement 4.Those with previous history of use of cyclophosphamide, prednisolone or other immunosuppressive agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is to analyse the effect of low dose intravenous cyclophosphamide on skin sclerosis as assessed by modified Rodnan skin score at 2 months, 4 months of starting treatment and the end of treatment. Further follow up of these patients will be done by revaluations 6 months and one year after the completion of treatment.Timepoint: 2 months, 4 months ,6 months 12 months,18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess side effects of cyclophosphamide pulse therapyTimepoint: 6 months,12 months,18 months | — |
Countries
India
Contacts
Public ContactAnza Khader
Government Medical college ,Kozhikode
Outcome results
None listed